IU Health administers first FDA-approved Pixclara dose in the U.S.

IU Health recently administered the first FDA‑approved dose of Pixclara in the United States. This marks a major step forward in care for patients facing aggressive brain cancers. Pixclara is a specialized imaging agent that lights up active tumor cells during a PET scan, helping clinicians see tumor activity more clearly and target treatment with greater precision. This gives patients access to better monitoring and more personalized care.

Krystyna Chadzichristos, who has been courageously battling glioblastoma for 18 months, received the first dose at the IU Health Neuroscience Center. “I’m very positive, and I hope this will help me get better soon.”